Focal segmental glomerulosclerosis associated with the use of the IL-23 inhibitor guselkumab.

Autor: Stryckers M; Department of Nephrology, H. Hart-Ziekenhuis, Lier, Belgium., Van Oevelen S; Department of Nephrology, H. Hart-Ziekenhuis, Lier, Belgium., Koshy P; Department of Pathology, University Hospitals Leuven, Leuven, Belgium., Sprangers B; Department of Nephrology, Ziekenhuis Oost-Limburg, Genk, Belgium.; Department of Immunology and Infection, Biomedical Research Institute of the Hasselt University, Diepenbeek, Belgium., Van Craenenbroeck AH; Department of Microbiology and Immunology, Laboratory of Nephrology of the KU Leuven, LeuvenBelgium.; Department of Neprology, University Hospitals Leuven, Leuven, Belgium.
Jazyk: angličtina
Zdroj: Clinical kidney journal [Clin Kidney J] 2023 Jul 06; Vol. 16 (10), pp. 1701-1702. Date of Electronic Publication: 2023 Jul 06 (Print Publication: 2023).
DOI: 10.1093/ckj/sfad161
Abstrakt: We report a case of a 38-year-old man who developed a nephrotic syndrome shortly after the start of guselkumab for the treatment of plaque psoriasis. Renal biopsy showed focal segmental glomerulosclerosis (FSGS). The clinical course of our case is highly suspect for drug-induced FSGS since the nephrotic syndrome resolved after cessation of the drug without relapse (2 years of follow-up). To the best of our knowledge, this is the first case describing FSGS lesions associated with the use of an interleukin-23 inhibitor.
Competing Interests: B.S. and A.H.V.C. are members of the CKJ Editorial Board.
(© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje